Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.

The article discusses research which investigated safety and effectiveness of rituximab in anti-synthetase antibody positive and negative patients with idiopathic inflammatory myopathy (IIM). Topics explored include the clinical characteristics and prevalence of IIM, the selection and evaluation of patients from the Swedish Rheumatology Quality Register, and brief details about the rituximab dosage administered and patient outcomes observed.